Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID-19: Daily Top 10 Papers


  Free Subscription

Articles published in Am Heart J

Retrieve available abstracts of 187 articles:
HTML format

Single Articles

    July 2021
  1. FREYER L, von Stulpnagel L, Spielbichler P, Sappler N, et al
    Rationale and design of a digital trial using smartphones to detect subclinical atrial fibrillation in a population at risk: The eHealth-based Bavarian Alternative Detection of Atrial Fibrillation (eBRAVE-AF) trial.
    Am Heart J. 2021 Jul 9. pii: S0002-8703(21)00164.
    PubMed     Abstract available

    June 2021
  2. KUMAR N, Xu H, Garg N, Pandey A, et al
    Patient Characteristics, Care Patterns, and Outcomes of Atrial Fibrillation Associated Hospitalizations in Patients with Chronic Kidney Disease and End-Stage Renal Disease.
    Am Heart J. 2021 Jun 30. pii: S0002-8703(21)00175.
    PubMed     Abstract available

  3. WHEELOCK KM, Kratz A, Lathkar-Pradhan S, Najarian K, et al
    Association between Symptoms, Affect and Heart Rhythm in Patients with Persistent or Paroxysmal Atrial Fibrillation: An Ambulatory Pilot Study.
    Am Heart J. 2021 Jun 19. pii: S0002-8703(21)00150.
    PubMed     Abstract available

  4. SZUMMER K, Perino AC, Fan J, Kothari M, et al
    Association of kidney function and atrial fibrillation progression to clinical outcomes in patients with cardiac implantable electronic devices.
    Am Heart J. 2021 Jun 9. pii: S0002-8703(21)00149.
    PubMed     Abstract available

    May 2021
  5. KITTIPIBUL V, Blumer V, Hernandez GA, Fudim M, et al
    Pre-operative Atrial Fibrillation and Early Right Ventricular Failure after Left Ventricular Assist Device Implantation: A Systematic Review and Meta-Analysis.
    Am Heart J. 2021 May 23. pii: S0002-8703(21)00138.
    PubMed     Abstract available

  6. YAO X, Attia ZI, Behnken EM, Walvatne K, et al
    Batch Enrollment for an Artificial Intelligence-Guided Intervention to Lower Neurologic Events in Patients with Undiagnosed Atrial Fibrillation (BEAGLE): Rationale and design of a digital clinical trial.
    Am Heart J. 2021 May 22. pii: S0002-8703(21)00135.
    PubMed     Abstract available

  7. HESS PL, Gosch KL, Jani SM, Varosy PD, et al
    Use of Oral Anticoagulants in Patients with Valvular Atrial Fibrillation: Findings From the NCDR PINNACLE Registry(R).
    Am Heart J. 2021 May 22. pii: S0002-8703(21)00120.
    PubMed     Abstract available

  8. MADSEN JMM, Jacobsen MRR, Sabbah M, Topal DGG, et al
    Long-Term Prognostic Outcomes and Implication of Oral Anticoagulants in Patients with New-Onset Atrial Fibrillation following ST-Segment Elevation Myocardial Infarction.
    Am Heart J. 2021 May 3. pii: S0002-8703(21)00114.
    PubMed     Abstract available

    April 2021
  9. LUBITZ SA, Faranesh AZ, Atlas SJ, McManus DD, et al
    Rationale and Design of a Large Population Study to Validate Software for the Assessment of Atrial Fibrillation from Data Acquired by a Consumer Tracker or Smartwatch: The Fitbit Heart Study.
    Am Heart J. 2021 Apr 15. pii: S0002-8703(21)00093.
    PubMed     Abstract available

  10. MARTIN AC, Hausleiter J, Karam N
    Intra-procedural unfractionated heparin monitoring and uninterrupted direct oral anticoagulants: An unheeded issue in transcatheter mitral valve repair procedures.
    Am Heart J. 2021;234:136-137.

    March 2021
  11. TURAKHIA M, Sundaram V, Smith SN, Ding V, et al
    Efficacy of a Centralized, Blended Electronic and Human Intervention to Improve Direct Oral Anticoagulant Adherence: Smartphones to improve rivaroxaban ADHEREnce in Atrial Fibrillation (SmartADHERE) A Randomized Clinical Trial: SmartADHERE rivaroxaban
    Am Heart J. 2021 Mar 4. pii: S0002-8703(21)00065.
    PubMed     Abstract available

  12. CHERY GS, Kamp N, Kosinski AS, Schmidler GS, et al
    Response to: The paradox of implantable cardioverter-defibrillator: When guidelines play against care improvement.
    Am Heart J. 2021;233:151-152.

  13. DISERTORI M, Mase M, Rigoni M, Ravelli F, et al
    The paradox of implantable cardioverter-defibrillator: When guidelines may play against care improvement.
    Am Heart J. 2021;233:149-150.

  14. CHEW DS, Sacks NC, Emden MR, Preib MT, et al
    Trends in health care resource use and expenditures in patients with newly diagnosed paroxysmal supraventricular tachycardia in the United States.
    Am Heart J. 2021;233:132-140.
    PubMed     Abstract available

    February 2021
  15. AKAO M, Yasuda S, Kaikita K, Ako J, et al
    Rivaroxaban Monotherapy versus Combination Therapy According to Patient Risk of Stroke and Bleeding in Atrial Fibrillation and Stable Coronary Disease: AFIRE trial sub-analysis.
    Am Heart J. 2021 Feb 28. pii: S0002-8703(21)00063.
    PubMed     Abstract available

  16. BLUMER V, Rivera M, Corbalan R, Becker RC, et al
    Rivaroxaban versus Warfarin in Patients with Atrial Fibrillation Enrolled in Latin America: Insights from ROCKET AF.
    Am Heart J. 2021 Feb 8. pii: S0002-8703(21)00036.
    PubMed     Abstract available

    January 2021
  17. SEN S, Redd K, Trivedi T, Moss K, et al
    Periodontal Disease, Atrial Fibrillation and Stroke.
    Am Heart J. 2021 Jan 24. pii: S0002-8703(21)00013.
    PubMed     Abstract available

  18. DE GROOT JR, Ruff CT, Murphy SA, Hamershock RA, et al
    Edoxaban versus Warfarin in Patients with Atrial Fibrillation in Relation to the Risk of Stroke: A Secondary Analysis of the ENGAGE AF-TIMI 48 Study.
    Am Heart J. 2021 Jan 22. pii: S0002-8703(21)00017.
    PubMed     Abstract available

  19. R P, G W, J R, M T, et al
    A Randomized Ablation-based atrial Fibrillation rhythm control versus rate control Trial in patients with heart failure and high burden Atrial Fibrillation.
    Am Heart J. 2021 Jan 17. pii: S0002-8703(21)00016.
    PubMed     Abstract available

  20. AKAO M, Yamashita T, Suzuki S, Okumura K, et al
    Corrigendum to "Impact of creatinine clearance on clinical outcomes in elderly atrial fibrillation patients receiving apixaban: J-ELD AF Registry sub-analysis" [Am Heart J, 223 (2020), 23-33].
    Am Heart J. 2021 Jan 8. pii: S0002-8703(20)30404.

  21. TOMASDOTTIR M, Held C, Hadziosmanovic N, Westerbergh J, et al
    Risk Markers of Incident Atrial Fibrillation in Patients with Coronary Heart Disease.
    Am Heart J. 2021 Jan 2. pii: S0002-8703(20)30425.
    PubMed     Abstract available

  22. TSENG WC, Huang CN, Chiu SN, Lu CW, et al
    Long-term outcomes of arrhythmia and distinct electrophysiological features in congenitally corrected transposition of the great arteries in an Asian cohort.
    Am Heart J. 2021;231:73-81.
    PubMed     Abstract available

  23. YERASI C, Tripathi B, Wang Y, Forrestal BJ, et al
    National trends and 30-day readmission rates for next-day-discharge transcatheter aortic valve replacement: An analysis from the Nationwide Readmissions Database, 2012-2016.
    Am Heart J. 2021;231:25-31.
    PubMed     Abstract available

    December 2020
  24. ROME BN, Gagne JJ, Avorn J, Kesselheim AS, et al
    Non-Warfarin Oral Anticoagulant Copayments and Adherence in Atrial Fibrillation:A Population-Based Cohort Study.
    Am Heart J. 2020 Dec 21. pii: S0002-8703(20)30412.
    PubMed     Abstract available

  25. CARNICELLI AP, Hong H, Giugliano RP, Connolly SJ, et al
    Individual Patient Data from the Pivotal Randomized Controlled Trials of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation (COMBINE AF): Design and Rationale: From the COMBINE AF (A COllaboration between Multiple instit
    Am Heart J. 2020 Dec 6. pii: S0002-8703(20)30401.
    PubMed     Abstract available

  26. KHAN H, Hanif M, Khan MA, Mirza E, et al
    Letter to the editor: Discontinuation rates of warfarin versus direct acting oral anticoagulants in clinical practice.
    Am Heart J. 2020;230:101.

    November 2020
  27. OVERWYK KJ, Yin X, Tong X, King SMC, et al
    Defect-free Care trends in the Paul Coverdell National Acute Stroke Program, 2008-2018.
    Am Heart J. 2020 Nov 27. pii: S0002-8703(20)30392.
    PubMed     Abstract available

  28. PERETTO G, De Luca G, Campochiaro C, Palmisano A, et al
    Telemedicine in myocarditis: Evolution of a mutidisciplinary "disease unit" at the time of COVID-19 pandemic.
    Am Heart J. 2020;229:121-126.
    PubMed     Abstract available

  29. LACHTRUPP CL, Valente AM, Gurvitz M, Landzberg MJ, et al
    Interobserver agreement of the anatomic and physiological classification system for adult congenital heart disease.
    Am Heart J. 2020;229:92-99.
    PubMed     Abstract available

  30. YANNOPOULOS D, Kalra R, Kosmopoulos M, Walser E, et al
    Rationale and methods of the Advanced R(2)Eperfusion STrategies for Refractory Cardiac Arrest (ARREST) trial.
    Am Heart J. 2020;229:29-39.
    PubMed     Abstract available

    October 2020
  31. BOAS R, Thune JJ, Pehrson S, Kober L, et al
    Atrial fibrillation is a marker of increased mortality risk in non-ischemic heart failure - results from the DANISH Trial.
    Am Heart J. 2020 Oct 31. pii: S0002-8703(20)30359.
    PubMed     Abstract available

  32. NATHAN AS, Yang L, Geng Z, Dayoub EJ, et al
    Oral anticoagulant use in patients with atrial fibrillation and mitral valve repair.
    Am Heart J. 2020;232:1-9.
    PubMed     Abstract available

  33. NORDENSKJOLD AM, Agewall S, Atar D, Baron T, et al
    Randomized evaluation of beta blocker and ACE-inhibitor/angiotensin receptor blocker treatment in patients with myocardial infarction with non-obstructive coronary arteries (MINOCA-BAT): Rationale and design.
    Am Heart J. 2020;231:96-104.
    PubMed     Abstract available

  34. FRIEDMAN DJ, Emerek K, Kisslo J, Sogaard P, et al
    Left bundle branch block is associated with a similar Dyssynchronous phenotype in heart failure patients with Normal and reduced ejection fractions.
    Am Heart J. 2020 Oct 21. pii: S0002-8703(20)30338.
    PubMed     Abstract available

  35. IKENOUCHI T, Inaba O, Takamiya T, Inamura Y, et al
    The impact of left atrium size on selection of the pulmonary vein isolation method for atrial fibrillation: Cryoballoon or radiofrequency catheter ablation.
    Am Heart J. 2020 Oct 21. pii: S0002-8703(20)30347.
    PubMed     Abstract available

  36. GUIMARAES HP, de Barros E Silva PGM, Liporace IL, Sampaio RO, et al
    A randomized clinical trial to evaluate the efficacy and safety of rivaroxaban in patients with bioprosthetic mitral valve and atrial fibrillation or flutter: Rationale and design of the RIVER trial.
    Am Heart J. 2020 Oct 9. pii: S0002-8703(20)30277.
    PubMed     Abstract available

  37. GONG IY, Atzema CL, Lega IC, Austin PC, et al
    Levothyroxine dose and risk of atrial fibrillation: a nested case-control study.
    Am Heart J. 2020 Oct 3. pii: S0002-8703(20)30272.
    PubMed     Abstract available

    August 2020
  38. KAWAKAMI H, Nolan MT, Phillips K, Scuffham PA, et al
    Cost-effectiveness of combined catheter ablation and left atrial appendage closure for symptomatic atrial fibrillation in patients with high stroke and bleeding risk.
    Am Heart J. 2020 Aug 18. pii: S0002-8703(20)30238.
    PubMed     Abstract available

  39. KWON S, Lee SR, Choi EK, Choe WS, et al
    Non-vitamin K antagonist oral anticoagulants in very elderly east Asians with atrial fibrillation: A nationwide population-based study.
    Am Heart J. 2020;229:81-91.
    PubMed     Abstract available

  40. MIRWAIS M, Reynolds M
    Extending physicians' reach in grasping AF symptoms.
    Am Heart J. 2020;226:250-251.

  41. KAHN PA, Gruen J, Thomas A, Ahmad T, et al
    Use and outcomes of wearable cardioverter-defibrillators in a large integrated academic health system.
    Am Heart J. 2020;226:232-234.

    July 2020
  42. AL-KHATIB SM, Pokorney SD, Al-Khalidi HR, Haynes K, et al
    Underuse of oral anticoagulants in privately insured patients with atrial fibrillation: A population being targeted by the IMplementation of a randomized controlled trial to imProve treatment with oral AntiCoagulanTs in patients with Atrial Fibrillati
    Am Heart J. 2020;229:110-117.
    PubMed     Abstract available

    June 2020
  43. PRASAD A, Panhwar S, Hendel RC, Sheikh O, et al
    COVID-19 and the cardiovascular system: A review of current data, summary of best practices, outline of controversies, and illustrative case reports.
    Am Heart J. 2020;226:174-187.
    PubMed     Abstract available

  44. DELURGIO DB, Ferguson E, Gill J, Blauth C, et al
    Convergence of Epicardial and Endocardial RF Ablation for the Treatment of Symptomatic Persistent AF (CONVERGE Trial): Rationale and design.
    Am Heart J. 2020;224:182-191.
    PubMed     Abstract available

    May 2020
  45. DEHGHANI P, Davidson LJ, Grines CL, Nayak K, et al
    North American COVID-19 ST-segment elevation myocardial infarction (NACMI) registry: Rationale, design, and implications.
    Am Heart J. 2020 May 16. pii: S0002-8703(20)30142.
    PubMed     Abstract available

  46. HA ACT, Stewart J, Klein G, Roy D, et al
    Impact of electrical cardioversion on quality of life for patients with symptomatic persistent atrial fibrillation: Is there a treatment expectation effect?
    Am Heart J. 2020;226:152-160.
    PubMed     Abstract available

  47. KATSUMATA Y, Kimura T, Kohsaka S, Ikemura N, et al
    Discrepancy in recognition of symptom burden among patients with atrial fibrillation.
    Am Heart J. 2020 May 6. pii: S0002-8703(20)30120.
    PubMed     Abstract available

  48. LOUNGANI RS, Rehorn MR, Newby LK, Katz JN, et al
    A care pathway for the cardiovascular complications of COVID-19: Insights from an institutional response.
    Am Heart J. 2020;225:3-9.
    PubMed     Abstract available

  49. WEIR MR, Ashton V, Moore KT, Shrivastava S, et al
    Response to letter regarding article "Rivaroxaban versus warfarin in patients with nonvalvular atrial fibrillation and stage IV-V chronic kidney disease".
    Am Heart J. 2020;223:111-112.

  50. SHOAR S, Shoar N, Naderan M, Modukuru VR, et al
    Regarding the publication "Rivaroxaban versus warfarin in patients with non-valvular atrial fibrillation and stage IV-V chronic kidney disease".
    Am Heart J. 2020;223:110.

    April 2020
  51. JACKSON LR 2ND, Kim S, Blanco R, Thomas L, et al
    Discontinuation rates of warfarin versus direct acting oral anticoagulants in US clinical practice: Results from Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II).
    Am Heart J. 2020;226:85-93.
    PubMed     Abstract available

  52. WALLACE BC, Allen LA, Knoepke CE, Glasgow RE, et al
    A multicenter trial of a shared DECision Support Intervention for Patients offered implantable Cardioverter-DEfibrillators: DECIDE-ICD rationale, design, Medicare changes, and pilot data.
    Am Heart J. 2020;226:161-173.
    PubMed     Abstract available

  53. AKAO M, Yamashita T, Suzuki S, Okumura K, et al
    Corrigendum to "Impact of creatinine clearance on clinical outcomes in elderly atrial fibrillation patients receiving apixaban: J-ELD AF Registry subanalysis" Am Heart J (2020).
    Am Heart J. 2020 Apr 13. pii: S0002-8703(20)30092.

    March 2020
  54. KARTHIKEYAN G, Connolly SJ, Ntsekhe M, Benz A, et al
    The INVICTUS rheumatic heart disease research program: Rationale, design and baseline characteristics of a randomized trial of rivaroxaban compared to vitamin K antagonists in rheumatic valvular disease and atrial fibrillation.
    Am Heart J. 2020;225:69-77.
    PubMed     Abstract available

  55. THIBERT MJ, Hawkins NM, Andrade JG
    Clinical decision support for atrial fibrillation in primary care: Steps forward.
    Am Heart J. 2020;224:54-56.

  56. COX JL, Parkash R, Foster GA, Xie F, et al
    Integrated Management Program Advancing Community Treatment of Atrial Fibrillation (IMPACT-AF): A cluster randomized trial of a computerized clinical decision support tool.
    Am Heart J. 2020;224:35-46.
    PubMed     Abstract available

  57. MIYAZAKI S, Horie T, Hachiya H, Hasegawa K, et al
    The mechanisms of recurrent atrial arrhythmias after second-generation cryoballoon ablation.
    Am Heart J. 2020;221:29-38.
    PubMed     Abstract available

    February 2020
  58. AKAO M, Yamashita T, Suzuki S, Okumura K, et al
    Impact of creatinine clearance on clinical outcomes in elderly atrial fibrillation patients receiving apixaban: J-ELD AF Registry subanalysis.
    Am Heart J. 2020;223:23-33.
    PubMed     Abstract available

  59. AKDIS D, Saguner AM, Burri H, Medeiros-Domingo A, et al
    Clinical predictors of left ventricular involvement in arrhythmogenic right ventricular cardiomyopathy.
    Am Heart J. 2020;223:34-43.
    PubMed     Abstract available

  60. HERNANDEZ-OJEDA J, Arbelo E, Jorda P, Borras R, et al
    The role of clinical assessment and electrophysiology study in Brugada syndrome patients with syncope.
    Am Heart J. 2020;220:213-223.
    PubMed     Abstract available

  61. ALI-AHMED F, Dalgaard F, Al-Khatib SM
    Sudden cardiac death in patients with myocarditis: Evaluation, risk stratification, and management.
    Am Heart J. 2020;220:29-40.
    PubMed     Abstract available

    January 2020
  62. WEIR MR, Ashton V, Moore KT, Shrivastava S, et al
    Rivaroxaban versus warfarin in patients with nonvalvular atrial fibrillation and stage IV-V chronic kidney disease.
    Am Heart J. 2020;223:3-11.
    PubMed     Abstract available

  63. MIURA K, Ikemura N, Kimura T, Katsumata Y, et al
    Treatment strategies and subsequent changes in the patient-reported quality-of-life among elderly patients with atrial fibrillation.
    Am Heart J. 2020;222:83-92.
    PubMed     Abstract available

  64. NGUYEN BO, Rienstra M, Hobbelt AH, Tijssen JGP, et al
    Optimal treatment of underlying conditions improves rhythm control outcome in atrial fibrillation - Data from RACE 3.
    Am Heart J. 2020 Jan 10. pii: S0002-8703(19)30345.

  65. LOUNGANI RS, Rehorn MR, Geurink KR, Coniglio AC, et al
    Outcomes following cardioversion for patients with cardiac amyloidosis and atrial fibrillation or atrial flutter.
    Am Heart J. 2020;222:26-29.
    PubMed     Abstract available

  66. DALGAARD F, North R, Pieper K, Fonarow GC, et al
    Risk of major cardiovascular and neurologic events with obstructive sleep apnea among patients with atrial fibrillation.
    Am Heart J. 2020;223:65-71.
    PubMed     Abstract available

    Atrial fibrillation detection using implantable cardiac monitors: Are we being too revealing?
    Am Heart J. 2020;219:137-139.

  68. REIFFEL JA, Verma A, Kowey PR, Halperin JL, et al
    Rhythm monitoring strategies in patients at high risk for atrial fibrillation and stroke: A comparative analysis from the REVEAL AF study.
    Am Heart J. 2020;219:128-136.
    PubMed     Abstract available

  69. LU DY, Ventoulis I, Liu H, Kudchadkar SM, et al
    Sex-specific cardiac phenotype and clinical outcomes in patients with hypertrophic cardiomyopathy.
    Am Heart J. 2020;219:58-69.
    PubMed     Abstract available

    December 2019
  70. TAZMINI K, Fraz MSA, Nymo SH, Stokke MK, et al
    Potassium infusion increases the likelihood of conversion of recent-onset atrial fibrillation-A single-blinded, randomized clinical trial.
    Am Heart J. 2019;221:114-124.
    PubMed     Abstract available

  71. MUHLESTEIN JB, Anderson JL, Bethea CF, Severance HW, et al
    Feasibility of combining serial smartphone single-lead electrocardiograms for the diagnosis of ST-elevation myocardial infarction.
    Am Heart J. 2019;221:125-135.
    PubMed     Abstract available

  72. HERMIDA JS, Chen J, Meyer C, Iacopino S, et al
    Cryoballoon catheter ablation versus antiarrhythmic drugs as a first-line therapy for patients with paroxysmal atrial fibrillation: Rationale and design of the international Cryo-FIRST study.
    Am Heart J. 2019;222:64-72.
    PubMed     Abstract available

  73. KALRA R, Shenoy C
    Identifying nonischemic cardiomyopathy patients who would benefit from an implantable cardioverter-defibrillator: Can late gadolinium enhancement on cardiovascular magnetic resonance imaging help?
    Am Heart J. 2019 Dec 17. pii: S0002-8703(19)30352.

  74. MEGALY M, Gossl M, Sorajja P, Anzia LE, et al
    Outcomes after pacemaker implantation in patients with new-onset left bundle-branch block after transcatheter aortic valve replacement.
    Am Heart J. 2019;218:128-132.
    PubMed     Abstract available

  75. MAZUREK M, Teutsch C, Diener HC, Dubner SJ, et al
    Safety and effectiveness of dabigatran at 2 years: Final outcomes from Phase II of the GLORIA-AF registry program.
    Am Heart J. 2019;218:123-127.
    PubMed     Abstract available

  76. EGBE AC, Najam M, Banala K, Vojjini R, et al
    Impact of atrial arrhythmia on survival in adults with tetralogy of Fallot.
    Am Heart J. 2019;218:1-7.
    PubMed     Abstract available

    November 2019
  77. JANKELSON L, Dai M, Bernstein S, Park D, et al
    Quantitative analysis of ablation technique predicts arrhythmia recurrence following atrial fibrillation ablation.
    Am Heart J. 2019;220:176-183.
    PubMed     Abstract available

  78. SUTTER JS, Lokhnygina Y, Daubert JP, Bahnson T, et al
    Safety and efficacy outcomes of left atrial posterior wall isolation compared to pulmonary vein isolation and pulmonary vein isolation with linear ablation for the treatment of persistent atrial fibrillation.
    Am Heart J. 2019;220:89-96.
    PubMed     Abstract available

  79. MAGGIONI AP, Dondi L, Andreotti F, Pedrini A, et al
    Four-year trends in oral anticoagulant use and declining rates of ischemic stroke among 194,030 atrial fibrillation patients drawn from a sample of 12 million people.
    Am Heart J. 2019;220:12-19.
    PubMed     Abstract available

  80. LORING Z, Shrader P, Allen LA, Blanco R, et al
    Guideline-directed therapies for comorbidities and clinical outcomes among individuals with atrial fibrillation.
    Am Heart J. 2019;219:21-30.
    PubMed     Abstract available

    October 2019
  81. GARCIA DA, Fisher DA, Mulder H, Wruck L, et al
    Gastrointestinal bleeding in patients with atrial fibrillation treated with Apixaban or warfarin: Insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial.
    Am Heart J. 2019;221:1-8.
    PubMed     Abstract available

  82. SLEE A, Saksena S
    Impact of initial heart failure emergence on clinical outcomes of atrial fibrillation patients in the AFFIRM trial.
    Am Heart J. 2019;220:1-11.
    PubMed     Abstract available

  83. BARRIO-LOPEZ MT, Ruiz-Canela M, Ramos P, Tercedor L, et al
    PREvention of recurrent arrhythmias with Mediterranean diet (PREDIMAR) study in patients with atrial fibrillation: Rationale, design and methods.
    Am Heart J. 2019;220:127-136.

  84. POKORNEY SD, Holmes DN, Shrader P, Thomas L, et al
    Patterns of amiodarone use and outcomes in clinical practice for atrial fibrillation.
    Am Heart J. 2019;220:145-154.
    PubMed     Abstract available

  85. DIEDERICHSEN SZ, Haugan KJ, Brandes A, Graff C, et al
    Incidence and predictors of atrial fibrillation episodes as detected by implantable loop recorder in patients at risk: From the LOOP study.
    Am Heart J. 2019 Oct 20. pii: S0002-8703(19)30267.
    PubMed     Abstract available

  86. SHAVADIA JS, Zheng Y, Green JB, Armstrong PW, et al
    Associations between beta-blocker therapy and cardiovascular outcomes in patients with diabetes and established cardiovascular disease.
    Am Heart J. 2019;218:92-99.
    PubMed     Abstract available

    August 2019
  87. KAMP NJ, Al-Khatib SM
    The subcutaneous implantable cardioverter-defibrillator in review.
    Am Heart J. 2019;217:131-139.
    PubMed     Abstract available

    July 2019
  88. LOEHR LR, Soliman EZ, Poon AK, Couper D, et al
    The prevalence of atrial fibrillation on 48-hour ambulatory electrocardiography in African Americans compared to Whites: The Atherosclerosis Risk in Communities (ARIC) study.
    Am Heart J. 2019;216:1-8.
    PubMed     Abstract available

    June 2019
  89. ASHBURNER JM, Atlas SJ, McManus DD, Chang Y, et al
    Design and rationale of a pragmatic trial integrating routine screening for atrial fibrillation at primary care visits: The VITAL-AF trial.
    Am Heart J. 2019;215:147-156.
    PubMed     Abstract available

    Response to a letter to the Editor by Prof Platonov and Prof Holmqvist.
    Am Heart J. 2019;212:160.

  91. PLATONOV PG, Holmqvist F
    Registry data on implantation of ICD is not necessarily reflective of an arrhythmic event.
    Am Heart J. 2019;212:158-159.

    May 2019
  92. QUAST ABE, Baalman SWE, Betts TR, Boersma LVA, et al
    Rationale and design of the PRAETORIAN-DFT trial: A prospective randomized CompArative trial of SubcutanEous ImplanTable CardiOverter-DefibrillatoR ImplANtation with and without DeFibrillation testing.
    Am Heart J. 2019;214:167-174.
    PubMed     Abstract available

  93. VALDERRABANO M, Peterson LE, Bunge R, Prystash M, et al
    Vein of Marshall ethanol infusion for persistent atrial fibrillation: VENUS and MARS clinical trial design.
    Am Heart J. 2019;215:52-61.
    PubMed     Abstract available

  94. MENTIAS A, Shantha G, Adeola O, Barnes GD, et al
    Role of diabetes and insulin use in the risk of stroke and acute myocardial infarction in patients with atrial fibrillation: A Medicare analysis.
    Am Heart J. 2019;214:158-166.
    PubMed     Abstract available

  95. ALEXANDRE J, Ollitrault P, Fischer MO, Fellahi JL, et al
    Spironolactone and perioperative atrial fibrillation occurrence in cardiac surgery patients: Rationale and design of the ALDOCURE trial.
    Am Heart J. 2019;214:88-96.
    PubMed     Abstract available

  96. MANN I, Sasikaran T, Sandler B, Babalis D, et al
    Ablation versus Anti-Arrhythmic Therapy for Reducing All Hospital Episodes from Recurrent Atrial Fibrillation (AVATAR-AF): Design and rationale.
    Am Heart J. 2019;214:36-45.
    PubMed     Abstract available

  97. HARSKAMP RE, Granger TM, Clare RM, White KR, et al
    Peripheral blood metabolite profiles associated with new onset atrial fibrillation.
    Am Heart J. 2019;211:54-59.
    PubMed     Abstract available

  98. LAKKIREDDY D, Windecker S, Thaler D, Sondergaard L, et al
    Rationale and design for AMPLATZER Amulet Left Atrial Appendage Occluder IDE randomized controlled trial (Amulet IDE Trial).
    Am Heart J. 2019;211:45-53.
    PubMed     Abstract available

    April 2019
  99. INOHARA T, Shrader P, Pieper K, Blanco RG, et al
    Treatment of atrial fibrillation with concomitant coronary or peripheral artery disease: Results from the outcomes registry for better informed treatment of atrial fibrillation II.
    Am Heart J. 2019;213:81-90.
    PubMed     Abstract available

  100. HAAS S, Camm AJ, Bassand JP, Angchaisuksiri P, et al
    Predictors of NOAC versus VKA use for stroke prevention in patients with newly diagnosed atrial fibrillation: Results from GARFIELD-AF.
    Am Heart J. 2019;213:35-46.
    PubMed     Abstract available

  101. BOL ME, Suverein MM, Lorusso R, Delnoij TSR, et al
    Early initiation of extracorporeal life support in refractory out-of-hospital cardiac arrest: Design and rationale of the INCEPTION trial.
    Am Heart J. 2019;210:58-68.
    PubMed     Abstract available

    March 2019
  102. LIP GYH, Mauri L, Montalescot G, Ozkor M, et al
    Relationship of stroke and bleeding risk profiles to efficacy and safety of dabigatran dual therapy versus warfarin triple therapy in atrial fibrillation after percutaneous coronary intervention: An ancillary analysis from the RE-DUAL PCI trial.
    Am Heart J. 2019;212:13-22.
    PubMed     Abstract available

    February 2019
  103. PETERSON ED, Ashton V, Chen YW, Wu B, et al
    Comparative effectiveness, safety, and costs of rivaroxaban and warfarin among morbidly obese patients with atrial fibrillation.
    Am Heart J. 2019;212:113-119.
    PubMed     Abstract available

    January 2019
  104. MADHAVAN M, Holmes DN, Piccini JP, Ansell JE, et al
    Association of frailty and cognitive impairment with benefits of oral anticoagulation in patients with atrial fibrillation.
    Am Heart J. 2019;211:77-89.
    PubMed     Abstract available

  105. TURAKHIA MP, Desai M, Hedlin H, Rajmane A, et al
    Rationale and design of a large-scale, app-based study to identify cardiac arrhythmias using a smartwatch: The Apple Heart Study.
    Am Heart J. 2019;207:66-75.
    PubMed     Abstract available

    December 2018
  106. BOURSIQUOT BC, Larson JC, Shalash OA, Vitolins MZ, et al
    Vitamin D with calcium supplementation and risk of atrial fibrillation in postmenopausal women.
    Am Heart J. 2018;209:68-78.
    PubMed     Abstract available

    November 2018
  107. ALEXANDER KP, Brouwer MA, Mulder H, Vinereanu D, et al
    Outcomes of apixaban versus warfarin in patients with atrial fibrillation and multi-morbidity: Insights from the ARISTOTLE trial.
    Am Heart J. 2018 Nov 22. pii: S0002-8703(18)30296.
    PubMed     Abstract available

  108. COHEN AA, Heidbuchel H, Le Heuzey JY, De Caterina R, et al
    Spontaneous conversion in patients with non-valvular atrial fibrillation planned for electrical cardioversion: A subanalysis of the EdoxabaN versus warfarin in subjectS UndeRgoing cardiovErsion Of Atrial Fibrillation (ENSURE-AF) trial.
    Am Heart J. 2018 Nov 22. pii: S0002-8703(18)30304.

  109. FARRIS GR, Smith BG, Oates ET, Colon C, et al
    New atrial fibrillation diagnosed by 30-day rhythm monitoring.
    Am Heart J. 2018;209:29-35.
    PubMed     Abstract available

  110. TRAN HV, Ash AS, Gore JM, Darling CE, et al
    Twenty-five year trends (1986-2011) in hospital incidence and case-fatality rates of ventricular tachycardia and ventricular fibrillation complicating acute myocardial infarction.
    Am Heart J. 2018;208:1-10.
    PubMed     Abstract available

    October 2018
  111. FAWZY AM, Olshansky B, Lip GYH
    Frailty and multi-morbidities should not govern oral anticoagulation therapy prescribing for patients with atrial fibrillation.
    Am Heart J. 2018 Oct 31. pii: S0002-8703(18)30297.

  112. PERINO AC, Leef GC, Cluckey A, Yunus FN, et al
    Secular trends in success rate of catheter ablation for atrial fibrillation: The SMASH-AF cohort.
    Am Heart J. 2018 Oct 29. pii: S0002-8703(18)30302.
    PubMed     Abstract available

  113. POKORNEY SD, Gersh BJ, Ahmad A, Al-Khatib SM, et al
    Stroke prevention in atrial fibrillation: Closing the gap.
    Am Heart J. 2018;210:29-38.

  114. ANDRADE JG, Champagne J, Deyell MW, Essebag V, et al
    A randomized clinical trial of early invasive intervention for atrial fibrillation (EARLY-AF) - methods and rationale.
    Am Heart J. 2018;206:94-104.
    PubMed     Abstract available

    September 2018
  115. EYSENCK W, van Zalen J, Freemantle N, Lloyd G, et al
    Central arteriovenous anastomosis for the treatment of patients with uncontrolled hypertension and paroxysmal AF.
    Am Heart J. 2018 Sep 29. pii: S0002-8703(18)30279.
    PubMed     Abstract available

  116. REIMOLD FR, Reynolds MR
    Proarrhythmia and death with antiarrhythmic drugs for atrial fibrillation, and the unfulfilled promise of comparative effectiveness research.
    Am Heart J. 2018 Sep 12. pii: S0002-8703(18)30254.

    August 2018
  117. VAN MIEGHEM NM, Unverdorben M, Valgimigli M, Mehran R, et al
    EdoxabaN Versus standard of care and theIr effectS on clinical outcomes in pAtients havinG undergonE Transcatheter Aortic Valve Implantation in Atrial Fibrillation-Rationale and design of the ENVISAGE-TAVI AF trial.
    Am Heart J. 2018;205:63-69.
    PubMed     Abstract available

  118. FRIBERG L
    Ventricular arrhythmia and death among atrial fibrillation patients using anti-arrhythmic drugs.
    Am Heart J. 2018;205:118-127.
    PubMed     Abstract available

  119. LI L, Selvin E, Lutsey PL, Hoogeveen RC, et al
    Association of N-terminal pro B-type natriuretic peptide (NT-proBNP) change with the risk of atrial fibrillation in the ARIC cohort.
    Am Heart J. 2018;204:119-127.
    PubMed     Abstract available

  120. DINOV B, Oebel S, Hilbert S, Loebe S, et al
    Characteristics of the ablation lesions in cardiac magnetic resonance imaging after radiofrequency ablation of ventricular arrhythmias in relation to the procedural success.
    Am Heart J. 2018;204:68-75.
    PubMed     Abstract available

    July 2018
  121. PICCINI JP, Calkins H
    Catheter ablation of rotational activity in atrial fibrillation: A barren oasis?
    Am Heart J. 2018 Jul 31. pii: S0002-8703(18)30229.

  122. GUNDLUND A, Kumler T, Olesen JB, Bonde AN, et al
    Comparative thromboembolic risk in atrial fibrillation patients with and without a concurrent infection.
    Am Heart J. 2018;204:43-51.
    PubMed     Abstract available

  123. BALDERSTON JR, Gertz ZM, Ellenbogen KA, Schaaf KP, et al
    Association between ventricular fibrillation amplitude immediately prior to defibrillation and defibrillation success in out-of-hospital cardiac arrest.
    Am Heart J. 2018;201:72-76.
    PubMed     Abstract available

  124. PASSMAN R
    Atrial fibrillation and stroke: The more we learn, the less we understand.
    Am Heart J. 2018;201:158-159.

    June 2018
  125. CHI G, Kerneis M, Kalayci A, Liu Y, et al
    Safety and efficacy of non-vitamin K oral anticoagulant for atrial fibrillation patients after percutaneous coronary intervention: A bivariate analysis of the PIONEER AF-PCI and RE-DUAL PCI trial.
    Am Heart J. 2018;203:17-24.
    PubMed     Abstract available

  126. ATZEMA CL, Dorian P, Fang J, Tu JV, et al
    A clinical decision instrument to predict 30-day death and cardiovascular hospitalizations after an emergency department visit for atrial fibrillation: The Atrial Fibrillation in the Emergency Room, Part 2 (AFTER2) study.
    Am Heart J. 2018;203:85-92.
    PubMed     Abstract available

  127. PASTORI D, Pignatelli P, Cribari F, Carnevale R, et al
    Time to therapeutic range (TtTR), anticoagulation control, and cardiovascular events in vitamin K antagonists-naive patients with atrial fibrillation.
    Am Heart J. 2018;200:32-36.
    PubMed     Abstract available

  128. LUBITZ SA, Khurshid S, Weng LC, Doros G, et al
    Predictors of oral anticoagulant non-prescription in patients with atrial fibrillation and elevated stroke risk.
    Am Heart J. 2018;200:24-31.
    PubMed     Abstract available

  129. LOPES RD, Vora AN, Liaw D, Granger CB, et al
    An open-Label, 2 x 2 factorial, randomized controlled trial to evaluate the safety of apixaban vs. vitamin K antagonist and aspirin vs. placebo in patients with atrial fibrillation and acute coronary syndrome and/or percutaneous coronary intervention:
    Am Heart J. 2018;200:17-23.
    PubMed     Abstract available

  130. CHEN ST, Hellkamp AS, Becker RC, Berkowitz SD, et al
    Impact of polyvascular disease on patients with atrial fibrillation: Insights from ROCKET AF.
    Am Heart J. 2018;200:102-109.
    PubMed     Abstract available

    May 2018
  131. PICCINI JP, Connolly SJ, Abraham WT, Healey JS, et al
    A genotype-directed comparative effectiveness trial of Bucindolol and metoprolol succinate for prevention of symptomatic atrial fibrillation/atrial flutter in patients with heart failure: Rationale and design of the GENETIC-AF trial.
    Am Heart J. 2018;199:51-58.
    PubMed     Abstract available

  132. PACKER DL, Mark DB, Robb RA, Monahan KH, et al
    Catheter Ablation versus Antiarrhythmic Drug Therapy for Atrial Fibrillation (CABANA) Trial: Study Rationale and Design.
    Am Heart J. 2018;199:192-199.
    PubMed     Abstract available

  133. YAO X, Gersh BJ, Sangaralingham LR, Shah ND, et al
    Risk of cardiovascular events and incident atrial fibrillation in patients without prior atrial fibrillation: Implications for expanding the indications for anticoagulation.
    Am Heart J. 2018;199:137-143.
    PubMed     Abstract available

  134. ECKMAN MH, Costea A, Attari M, Munjal J, et al
    Shared decision-making tool for thromboprophylaxis in atrial fibrillation - A feasibility study.
    Am Heart J. 2018;199:13-21.
    PubMed     Abstract available

  135. KIM D, Yang PS, Jang E, Yu HT, et al
    10-year nationwide trends of the incidence, prevalence, and adverse outcomes of non-valvular atrial fibrillation nationwide health insurance data covering the entire Korean population.
    Am Heart J. 2018;202:20-26.
    PubMed     Abstract available

    April 2018
  136. O'CONNOR AM, Smith AH, Crum K, Edwards TL, et al
    Analysis of clinical and candidate genetic risk factors for postoperative atrial tachycardia after congenital heart surgery in infants.
    Am Heart J. 2018;202:1-4.
    PubMed     Abstract available

  137. PERERA KS, Sharma M, Connolly SJ, Wang J, et al
    Stroke type and severity in patients with subclinical atrial fibrillation: An analysis from the Asymptomatic Atrial Fibrillation and Stroke Evaluation in Pacemaker Patients and the Atrial Fibrillation Reduction Atrial Pacing Trial (ASSERT).
    Am Heart J. 2018 Apr 18. pii: S0002-8703(18)30120.
    PubMed     Abstract available

  138. COX JL, Parkash R, Abidi SS, Thabane L, et al
    Optimizing primary care management of atrial fibrillation: The rationale and methods of the Integrated Management Program Advancing Community Treatment of Atrial Fibrillation (IMPACT-AF) study.
    Am Heart J. 2018;201:149-157.
    PubMed     Abstract available

  139. HUISMAN MV, Rothman KJ, Paquette M, Teutsch C, et al
    Two-year follow-up of patients treated with dabigatran for stroke prevention in atrial fibrillation: Global Registry on Long-Term Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF) registry.
    Am Heart J. 2018;198:55-63.
    PubMed     Abstract available

  140. FAUCHIER L, Bisson A, Clementy N, Vourc'h P, et al
    Changes in glomerular filtration rate and outcomes in patients with atrial fibrillation.
    Am Heart J. 2018;198:39-45.
    PubMed     Abstract available

  141. HIJAZI Z, Hohnloser SH, Oldgren J, Andersson U, et al
    Efficacy and safety of dabigatran compared with warfarin in patients with atrial fibrillation in relation to renal function over time-A RE-LY trial analysis.
    Am Heart J. 2018;198:169-177.

  142. MIYAZAWA K, Pastori D, Lip GYH
    Changes in renal function in patients with atrial fibrillation: Efficacy and safety of the non-vitamin K antagonist oral anticoagulants.
    Am Heart J. 2018;198:166-168.

    March 2018
  143. GARG PK, Bartz TM, Norby FL, Jorgensen NW, et al
    Association of lipoprotein-associated phospholipase A2 and risk of incident atrial fibrillation: Findings from 3 cohorts.
    Am Heart J. 2018;197:62-69.
    PubMed     Abstract available

  144. KOPIN D, Jones WS, Sherwood MW, Wojdyla DM, et al
    Percutaneous coronary intervention and antiplatelet therapy in patients with atrial fibrillation receiving apixaban or warfarin: Insights from the ARISTOTLE trial.
    Am Heart J. 2018;197:133-141.
    PubMed     Abstract available

  145. VERMA A, Ha ACT, Kirchhof P, Hindricks G, et al
    The Optimal Anti-Coagulation for Enhanced-Risk Patients Post-Catheter Ablation for Atrial Fibrillation (OCEAN) trial.
    Am Heart J. 2018;197:124-132.
    PubMed     Abstract available

  146. RIVERA-CARAVACA JM, Roldan V, Esteve-Pastor MA, Valdes M, et al
    Prediction of long-term net clinical outcomes using the TIMI-AF score: Comparison with CHA2DS2-VASc and HAS-BLED.
    Am Heart J. 2018;197:27-34.
    PubMed     Abstract available

    February 2018
  147. VRANCKX P, Lewalter T, Valgimigli M, Tijssen JG, et al
    Evaluation of the safety and efficacy of an edoxaban-based antithrombotic regimen in patients with atrial fibrillation following successful percutaneous coronary intervention (PCI) with stent placement: Rationale and design of the ENTRUST-AF PCI trial
    Am Heart J. 2018;196:105-112.
    PubMed     Abstract available

  148. LAURIDSEN KG, Schmidt AS, Adelborg K, Bach L, et al
    Effects of hyperoxia on myocardial injury following cardioversion-A randomized clinical trial.
    Am Heart J. 2018;196:97-104.
    PubMed     Abstract available

    January 2018
  149. LARSSON SC, Drca N, Jensen-Urstad M, Wolk A, et al
    Chocolate consumption and risk of atrial fibrillation: Two cohort studies and a meta-analysis.
    Am Heart J. 2018;195:86-90.
    PubMed     Abstract available

  150. YONG CM, Liu Y, Apruzzese P, Doros G, et al
    Association of insurance type with receipt of oral anticoagulation in insured patients with atrial fibrillation: A report from the American College of Cardiology NCDR PINNACLE registry.
    Am Heart J. 2018;195:50-59.
    PubMed     Abstract available

  151. CLARK NP, Douketis JD, Hasselblad V, Schulman S, et al
    Predictors of perioperative major bleeding in patients who interrupt warfarin for an elective surgery or procedure: Analysis of the BRIDGE trial.
    Am Heart J. 2018;195:108-114.
    PubMed     Abstract available

    December 2017
  152. OKUMURA K, Lip GYH, Akao M, Tanizawa K, et al
    Edoxaban for the management of elderly Japanese patients with atrial fibrillation ineligible for standard oral anticoagulant therapies: Rationale and design of the ELDERCARE-AF study.
    Am Heart J. 2017;194:99-106.
    PubMed     Abstract available

  153. ECKMAN MH, Costea A, Attari M, Munjal J, et al
    Atrial fibrillation decision support tool: Population perspective.
    Am Heart J. 2017;194:49-60.
    PubMed     Abstract available

  154. STEINBERG BA, Gao H, Shrader P, Pieper K, et al
    International trends in clinical characteristics and oral anticoagulation treatment for patients with atrial fibrillation: Results from the GARFIELD-AF, ORBIT-AF I, and ORBIT-AF II registries.
    Am Heart J. 2017;194:132-140.
    PubMed     Abstract available

    November 2017
  155. LIP GYH, Al-Saady N, Ezekowitz MD, Banach M, et al
    The relationship of renal function to outcome: A post hoc analysis from the EdoxabaN versus warfarin in subjectS UndeRgoing cardiovErsion of Atrial Fibrillation (ENSURE-AF) study.
    Am Heart J. 2017;193:16-22.
    PubMed     Abstract available

  156. DA COSTA A, Delolme C, Guichard JB, Gerbay A, et al
    Comparison of prevalence and management of left atrial appendage thrombi under old and new anticoagulants prior to left atrial catheter ablation.
    Am Heart J. 2017;193:8-15.
    PubMed     Abstract available

    October 2017
  157. MOJOLI M, Gersh BJ, Barioli A, Masiero G, et al
    Impact of atrial fibrillation on outcomes of patients treated by transcatheter aortic valve implantation: A systematic review and meta-analysis.
    Am Heart J. 2017;192:64-75.
    PubMed     Abstract available

  158. KESSLER M, Gonska B, Seeger J, Rottbauer W, et al
    Predictors of permanent pacemaker implantation after transfemoral aortic valve implantation with the Lotus valve.
    Am Heart J. 2017;192:57-63.
    PubMed     Abstract available

  159. VINEREANU D, Al-Khalidi HR, Rao MP, He W, et al
    Regional differences in presentation and antithrombotic treatment of patients with atrial fibrillation: Baseline characteristics from a clustered randomized trial to IMProve treatment with AntiCoagulanTs in patients with atrial fibrillation (IMPACT-AF
    Am Heart J. 2017;192:38-47.
    PubMed     Abstract available

  160. FASHANU OE, Norby FL, Aguilar D, Ballantyne CM, et al
    Galectin-3 and incidence of atrial fibrillation: The Atherosclerosis Risk in Communities (ARIC) study.
    Am Heart J. 2017;192:19-25.
    PubMed     Abstract available

    September 2017
  161. FRIEDMAN DJ, Al-Khatib SM, Zeitler EP, Han J, et al
    New York Heart Association class and the survival benefit from primary prevention implantable cardioverter defibrillators: A pooled analysis of 4 randomized controlled trials.
    Am Heart J. 2017;191:21-29.
    PubMed     Abstract available

  162. O'NEILL ES, Grande SW, Sherman A, Elwyn G, et al
    Availability of patient decision aids for stroke prevention in atrial fibrillation: A systematic review.
    Am Heart J. 2017;191:1-11.
    PubMed     Abstract available

    August 2017
  163. HIJAZI Z, Oldgren J, Andersson U, Connolly SJ, et al
    Growth-differentiation factor 15 and risk of major bleeding in atrial fibrillation: Insights from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial.
    Am Heart J. 2017;190:94-103.
    PubMed     Abstract available

  164. PROIETTI M, Airaksinen KEJ, Rubboli A, Schlitt A, et al
    Time in therapeutic range and major adverse outcomes in atrial fibrillation patients undergoing percutaneous coronary intervention: The Atrial Fibrillation Undergoing Coronary Artery Stenting (AFCAS) registry.
    Am Heart J. 2017;190:86-93.
    PubMed     Abstract available

  165. BERNSTEIN RA, Kamel H, Granger CB, Kowal RC, et al
    Stroke of Known Cause and Underlying Atrial Fibrillation (STROKE-AF) randomized trial: Design and rationale.
    Am Heart J. 2017;190:19-24.
    PubMed     Abstract available

  166. KIRCHHOF P, Blank BF, Calvert M, Camm AJ, et al
    Probing oral anticoagulation in patients with atrial high rate episodes: Rationale and design of the Non-vitamin K antagonist Oral anticoagulants in patients with Atrial High rate episodes (NOAH-AFNET 6) trial.
    Am Heart J. 2017;190:12-18.
    PubMed     Abstract available

    July 2017
  167. PERINI AP, Kutyifa V, Veazie P, Daubert JP, et al
    Effects of implantable cardioverter/defibrillator shock and antitachycardia pacing on anxiety and quality of life: A MADIT-RIT substudy.
    Am Heart J. 2017;189:75-84.
    PubMed     Abstract available

  168. STEINBERG BA, Shrader P, Thomas L, Ansell J, et al
    Factors associated with non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with new-onset atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II).
    Am Heart J. 2017;189:40-47.
    PubMed     Abstract available

  169. KUTYIFA V, Beck C, Brown MW, Cannom D, et al
    Multicenter Automatic Defibrillator Implantation Trial-Subcutaneous Implantable Cardioverter Defibrillator (MADIT S-ICD): Design and clinical protocol.
    Am Heart J. 2017;189:158-166.
    PubMed     Abstract available

  170. LOPES RD, Alings M, Connolly SJ, Beresh H, et al
    Rationale and design of the Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation (ARTESiA) trial.
    Am Heart J. 2017;189:137-145.
    PubMed     Abstract available

  171. HOLMES DR, Reddy VY, Buchbinder M, Stein K, et al
    The Assessment of the Watchman Device in Patients Unsuitable for Oral Anticoagulation (ASAP-TOO) trial.
    Am Heart J. 2017;189:68-74.
    PubMed     Abstract available

    June 2017
  172. GRAVES KG, May HT, Jacobs V, Bair TL, et al
    Atrial fibrillation incrementally increases dementia risk across all CHADS2 and CHA2DS2VASc strata in patients receiving long-term warfarin.
    Am Heart J. 2017;188:93-98.
    PubMed     Abstract available

  173. GRAFF S, Prior A, Fenger-Gron M, Christensen B, et al
    Does perceived stress increase the risk of atrial fibrillation? A population-based cohort study in Denmark.
    Am Heart J. 2017;188:26-34.
    PubMed     Abstract available

    May 2017
  174. GEHI AK, Doros G, Glorioso TJ, Grunwald GK, et al
    Factors associated with rhythm control treatment decisions in patients with atrial fibrillation-Insights from the NCDR PINNACLE registry.
    Am Heart J. 2017;187:88-97.
    PubMed     Abstract available

  175. KARLSSON LO, Nilsson S, Charitakis E, Bang M, et al
    Clinical decision support for stroke prevention in atrial fibrillation (CDS-AF): Rationale and design of a cluster randomized trial in the primary care setting.
    Am Heart J. 2017;187:45-52.
    PubMed     Abstract available

  176. DIEDERICHSEN SZ, Haugan KJ, Kober L, Hojberg S, et al
    Atrial fibrillation detected by continuous electrocardiographic monitoring using implantable loop recorder to prevent stroke in individuals at risk (the LOOP study): Rationale and design of a large randomized controlled trial.
    Am Heart J. 2017;187:122-132.
    PubMed     Abstract available

  177. PICCINI JP, Clark RL, Kowey PR, Mittal S, et al
    Long-term electrocardiographic safety monitoring in clinical drug development: A report from the Cardiac Safety Research Consortium.
    Am Heart J. 2017;187:156-169.
    PubMed     Abstract available

    April 2017
  178. EGBE AC, Connolly HM, Khan AR, Niaz T, et al
    Outcomes in adult Fontan patients with atrial tachyarrhythmias.
    Am Heart J. 2017;186:12-20.
    PubMed     Abstract available

  179. WAN C, Szymkiewicz SJ, Klein HU
    The impact of body mass index on the wearable cardioverter defibrillator shock efficacy and patient wear time.
    Am Heart J. 2017;186:111-117.
    PubMed     Abstract available

    March 2017
  180. SMITH WM, Riddell F, Madon M, Gleva MJ, et al
    Comparison of diagnostic value using a small, single channel, P-wave centric sternal ECG monitoring patch with a standard 3-lead Holter system over 24 hours.
    Am Heart J. 2017;185:67-73.
    PubMed     Abstract available

  181. KUPSKY DF, Ahmed AM, Sakr S, Qureshi WT, et al
    Cardiorespiratory fitness and incident heart failure: The Henry Ford ExercIse Testing (FIT) Project.
    Am Heart J. 2017;185:35-42.
    PubMed     Abstract available

    February 2017
  182. FANOLA CL, Mooney D, Cowan AJ, Ko D, et al
    Incidence of severe renal dysfunction among individuals taking warfarin and implications for non-vitamin K oral anticoagulants.
    Am Heart J. 2017;184:150-155.
    PubMed     Abstract available

  183. SORENSEN LL, Liang HY, Pinheiro A, Hilser A, et al
    Safety profile and utility of treadmill exercise in patients with high-gradient hypertrophic cardiomyopathy.
    Am Heart J. 2017;184:47-54.
    PubMed     Abstract available

    January 2017
  184. EGBE AC, Connolly HM, Niaz T, Yogeswaran V, et al
    Prevalence and outcome of thrombotic and embolic complications in adults after Fontan operation.
    Am Heart J. 2017;183:10-17.
    PubMed     Abstract available

    September 2016
  185. GILOTRA NA, Bennett MK, Shpigel A, Ahmed HM, et al
    Outcomes and predictors of recovery in acute-onset cardiomyopathy: A single-center experience of patients undergoing endomyocardial biopsy for new heart failure.
    Am Heart J. 2016;179:116-26.
    PubMed     Abstract available

    August 2016
  186. O'DONNELL MJ, Eikelboom JW, Yusuf S, Diener HC, et al
    Effect of apixaban on brain infarction and microbleeds: AVERROES-MRI assessment study.
    Am Heart J. 2016;178:145-50.
    PubMed     Abstract available

    July 2016
  187. TING R, Tejpal A, Finken L, Fisher M, et al
    Repatriation to referral hospital after reperfusion of STEMI patients transferred for primary percutaneous coronary intervention: Insights of a Canadian regional STEMI care system.
    Am Heart J. 2016;177:145-52.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Arrhythmias is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.